Orbis Diagnostics believes everyone should be empowered to understand their true health status, irrespective of who they are and where they live. High quality, accessible diagnostics enable individuals within society to make life-changing decisions with confidence.
Orbis brings together a proven team of world-leading scientists, backed by New Zealand’s largest early stage deep-tech investor, Pacific Channel. Orbis has developed the Arca, a ‘lab on a disk’ testing platform that uses proprietary microfluidic technology to miniaturise and automate accurate lab testing for use at the point of care. Orbis has trialed its technology on a wide range of fluid media and analytes, including measuring progesterone in milk to inform the timing of artificial insemination. With the outbreak of COVID-19, Orbis recognised how the unique features of the system could help people determine their relative level of immunity following vaccination and quickly repurposed the technology to deliver a quantitative immunity test for COVID-19. Following the introduction of new variants and changes to COVID-19 restrictions, Orbis adapted to the suit new testing demands and moved towards a broader system for the platform, enabling Orbis to take on infectious diseases and various different types of assays.
Orbis obtained its second patent (US 11618105) titled: Methods for establishing hydrophilic and hydrophobic areas on a surface of a substrate or film and associated microfluidic devices
At the Technology Investment Network 200 (TIN200) annual awards Orbis was named as one of the Pipeline Companies for 2022. The winning companies are selected based on an assessment of the innovation of their technology and the potential market opportunity.
Orbis was successfully granted its first patent (US 11565260) regarding Multi-chambered assay devices and associated methods, systems and apparatuses thereof for detection of analytes
Cooley, an American law firm with extensive IP experience, partners with Orbis Diagnostics
Orbis has undertaken a trial with Air New Zealand employees to significantly accelerate the development of the Orbis Arca, an automated immunity testing platform designed to accurately measure immunity to COVID-19 within 15 minutes at high-volume, point of need locations such as airports, pharmacies, and workplaces.
In addition, Orbis' technology has been selected for Sir Ian Taylor’s self-isolation pilot trial, measuring his immunity and protection from COVID-19 on the day of his departure from New Zealand. Read more here.
Orbis' immunity screening platform is here! We're really excited about our commercial prototype - which successfully miniaturizes the highly accurate testing available in the lab onto a desktop-sized machine, readying our COVID-19 immunity test for deployment at airports.
Orbis announces an exclusive partnership with leading biometrics company IDEMIA to develop and deploy a complete immunity testing platform solution for the air travel industry that enables the best passenger experience without compromising on security. Read the announcement here.
D&K Engineering, a San Diego-based global leader in product development, offers to productise and manufacture Orbis' system.
The COVID-19 pandemic clarified the need for a scalable quantitative antibody test to verify immunity at the point of need, and Orbis’ system was perfectly suited. The team pivoted to developing a COVID-19 immunity test, exploiting the advantages of an automated system designed for a non-lab environment.
Development of a quantitative progesterone detection test of cows milk to assist with timing of insemination of cows to optimize reproduction and avoid unnecessary culling of cows with silent heats.
Proof-of-concept demonstration of a miniaturised immunoassay on our proprietary microfluidic disks, able to measure protein and fat content of cow milk.
Orbis spun out of the Photon Factory, New Zealand's internationally-recognised research lab led by Scientific Co-Founder, Professor Cather Simpson. Orbis is the second company to originate in this lab, following Engender Technologies.